This is an upcoming trial to study a PD-1/CTLA-4 inhibitor combination with or without Regorafenib.

This is an upcoming trial to study a PD-1 inhibitor in combination with Fruquitinib.

This is an upcoming trial to study a 7p RAS vaccine.

This is an upcoming trial to study the impact of biomarker directed targeted systemic therapy.

This is an upcoming trial to study engineered TILs in colorectal patients with minimal residual disease or borderline resectable metastatic disease.

This is a Phase II trial studying anti-CSF1R antibody in patients with ctDNA positive colorectal cancer minimal residual disease after completion of standard therapies.

This is a Phase Ib, prospective, single arm, non-randomized, open-label clinical trial determining the efficacy of adjuvant trifluridine and tipiracil (TAS-102) in combination with irinotecan in patients with ctDNA positive colon adenocarcinoma.

This is a study designed to evaluate varying doses of TROP2-CAR-NK cells combined with cetuximab and their ability to clear ctDNA in patients with minimal residual colorectal cancer.

This is a Phase III trial studying atezolizumab and bevacizumab in ctDNA positive colorectal cancer patients with no evidence of cancer on imaging after completing standard therapies.

This is a single arm Phase II cohort of RO7198457 in patients with circulating tumor DNA (ctDNA) positive surgically resected Stage IV CRC after standard of care adjuvant therapy. The study will test whether the vaccine can reduce recurrence of the cancer.

This is a Phase I study to assess the safety and tolerability and to determine the recommended Phase 2 dose (RP2D) of E7386 in combination with other anticancer drug(s).

To determine if the detection of ctDNA after surgical resection of CLM can stratify patients into high and low-risk cohorts for early disease recurrence in order to inform post-operative adjuvant therapy.

This is a Phase I/II trial studying the side effects and best dose of SX-682 that can be given alone and in combination with nivolumab in treating patients with RAS-Mutated, microsatellite stable (MSS) colorectal cancer that has spread to other places in the body (metastatic) or cannot be removed by surgery (unresectable). SX-682 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Nivolumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving SX-682 alone and together with nivolumab may kill more tumor cells.

A study designed to evaluate the effects of vitamin D and aspirin supplementation, a plant-based diet, and physical activity on CRC patients with minimal residual disease. The study aims to assess whether such lifestyle changes can eradicate ctDNA in the blood and reduce cancer recurrence.

This is a multi-site, open-label, Phase II, randomized, trial to compare the efficacy of RO7198457 versus watchful waiting in patients with circulating tumor DNA (ctDNA) positive, surgically resected Stage II/III rectal or colon. The study will test whether the vaccine can reduce recurrence of the cancer.

This is a Phase II/III trial across North America cooperative groups to study what kind of chemotherapy to recommend to low risk, Stage III colon cancer (T1-3, N1) patients based on the presence or absence of ctDNA after surgery for colon cancer.

ctDNA positive patients randomized to FOLFIRI (12 cycles) or surveillance. If MSI-H, receive nivolumab (12 cycles). If BRAF mutation is present, receive encorafenib, binimetinib, and cetuximab (12 cycles).